The 36-month beta value for BLUE is also noteworthy at 0.77. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 5 rating it as “overweight,” 5 rating it as “hold,” and 1 rating it as “sell.”
The public float for BLUE is 189.83M, and at present, short sellers hold a 15.67% of that float. The average trading volume of BLUE on April 15, 2024 was 8.79M shares.
BLUE) stock’s latest price update
Bluebird bio Inc (NASDAQ: BLUE)’s stock price has decreased by -5.17 compared to its previous closing price of 1.16. However, the company has seen a -10.57% decrease in its stock price over the last five trading sessions. The Motley Fool reported 2024-04-13 that Bluebird Bio’s most recently approved gene editing therapy looks highly promising. Novavax has generated decent revenue from its coronavirus vaccine.
BLUE’s Market Performance
BLUE’s stock has fallen by -10.57% in the past week, with a monthly drop of -20.86% and a quarterly drop of -20.29%. The volatility ratio for the week is 8.07% while the volatility levels for the last 30 days are 8.87% for Bluebird bio Inc The simple moving average for the past 20 days is -15.01% for BLUE’s stock, with a -57.33% simple moving average for the past 200 days.
Analysts’ Opinion of BLUE
Morgan Stanley, on the other hand, stated in their research note that they expect to see BLUE reach a price target of $7, previously predicting the price at $3. The rating they have provided for BLUE stocks is “Equal-Weight” according to the report published on December 08th, 2023.
BLUE Trading at -12.46% from the 50-Day Moving Average
After a stumble in the market that brought BLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.11% of loss for the given period.
Volatility was left at 8.87%, however, over the last 30 days, the volatility rate increased by 8.07%, as shares sank -17.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.84% upper at present.
During the last 5 trading sessions, BLUE fell by -10.57%, which changed the moving average for the period of 200-days by -67.07% in comparison to the 20-day moving average, which settled at $1.2828. In addition, Bluebird bio Inc saw -20.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BLUE starting from Obenshain Andrew, who sale 6,095 shares at the price of $1.53 back on Mar 04 ’24. After this action, Obenshain Andrew now owns 279,998 shares of Bluebird bio Inc, valued at $9,311 using the latest closing price.
Klima Thomas J, the of Bluebird bio Inc, sale 4,573 shares at $1.53 during a trade that took place back on Mar 04 ’24, which means that Klima Thomas J is holding 124,840 shares at $6,986 based on the most recent closing price.
Stock Fundamentals for BLUE
Current profitability levels for the company are sitting at:
- -6.27 for the present operating margin
- -0.1 for the gross margin
The net margin for Bluebird bio Inc stands at -3.61. The total capital return value is set at -0.3. Equity return is now at value -47.81, with -16.08 for asset returns.
Based on Bluebird bio Inc (BLUE), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -0.91. The debt to equity ratio resting at 1.36. The interest coverage ratio of the stock is 1.45.
Currently, EBITDA for the company is -277.21 million with net debt to EBITDA at -0.61. When we switch over and look at the enterprise to sales, we see a ratio of 16.13. The receivables turnover for the company is 0.94for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.55.
Conclusion
In summary, Bluebird bio Inc (BLUE) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
